

# Global Fuchs Endothelial Corneal Dystrophy FECD Market To Reach \$251.47 Billion By 2029 With A Growth Rate Of 7.9%

*The Business Research Company's Fuchs Endothelial Corneal Dystrophy FECD Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, July 2, 2025

/EINPresswire.com/ -- In recent years, the Fuchs Endothelial Corneal

Dystrophy [FECD market](#) size has seen remarkable growth. The market, which was valued at \$171.48 billion in 2024, is forecast to grow to \$185.45 billion in 2025, reflecting a compound annual growth rate CAGR of 8.1%. The significant growth observed in the historic period can be linked to an increase in the prevalence of age-related eye disorders, a surge in demand for

corneal transplants, growing awareness and diagnosis rates, escalating adoption of minimally invasive surgical procedures, and a rise in investments in regenerative medicine.



Save 30% on all global market reports with code ONLINE30 - stay informed on tariff changes, macroeconomic trends, and more."

*The Business Research Company*

The Business  
Research Company

The Business Research Company



### What Is The Projected Future Growth Of The FECD Market Size?

The FECD market size is programmed for a strong growth pattern in the following years. It is projected to reach \$251.47 billion by 2029, growing at a CAGR of 7.9%. The anticipated growth in the forecast period can mainly be

attributed to the escalating accessibility of advanced diagnostic imaging, increased health expenditure, rising incidence rates of diabetes and hypertension, a growing number of specialty eye clinics, and advanced research on genetic and molecular mechanisms. Noteworthy trends projected for the forecast period include advancements in regenerative medicine, the integration of artificial intelligence in diagnosis, developments in bioengineered corneal grafts, improvements in surgical techniques, and the adoption of technological advancements in corneal imaging systems.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24542&type=smp>

### What Are The Key Drivers Propelling The Growth Of The FECD Market?

The increasing demand for corneal transplants is expected to drive the expansion of the FECD market. A corneal transplant refers to a surgical procedure that involves replacing a damaged or diseased cornea with healthy donor corneal tissue. This procedure helps to restore vision and eye function. The heightened demand for corneal transplants can be attributed to the increasing prevalence of corneal diseases, which often lead to vision impairment and require surgical intervention. The FECD condition, in particular, accelerates the need for corneal transplants by causing progressive damage to the corneal endothelium, which often necessitates surgical intervention. For example, in 2023, there was a 2.7% increase in domestic keratoplasty procedures, from 49,597 in 2022 to 50,925 in 2023, as reported by the Eye Bank Association of America, a US-based transplant association. Therefore, the escalating demand for corneal transplants is a primary driver spurring the growth of the FECD market.

### What Key Player Strategies Are Driving The FECD Market?

Prominent companies operating in the FECD market include Carl Zeiss Meditec, Santen Pharmaceutical Co. Ltd., Design Therapeutics Inc., Stealth BioTherapeutics Corp., ProQR Therapeutics N.V., Surrozen Inc., Cellusion Inc., Price Vision Group LLC, ActualEyes Inc., Arctic Vision Limited, Aurion Biotech Inc., Emmecell Inc., Invirsa Inc., KeraMed Inc., Kowa Company Ltd., Kuria Therapeutics Inc., Massachusetts Eye and Ear, MediciBIO Co. LTD., Prime Medicine Inc., and Trefoil Therapeutics.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/fuchs-endothelial-corneal-dystrophy-global-market-report>

### What Are The Emerging Trends In The FECD Market?

Leading companies in the FECD market are focusing on clinical trials to develop novel products, such as rho kinase inhibitors, aimed at improving corneal cell regeneration and vision restoration. These classes of drugs improve corneal cell regeneration and reduce cell stress by blocking the rho kinase pathway, making them promising for treating conditions such as FECD. For instance, in April 2023, Japan-based pharmaceutical company, Kowa Company Ltd., announced the launch of a global phase 3 clinical trial. This trial is designed to evaluate the safety and effectiveness of K-321 Ripasudil Hydrochloride Dihydrate ophthalmic solution in treating patients with FECD following descemetorhexis. This study aims to offer a nonsurgical treatment option for FECD, a progressive eye condition that often necessitates corneal transplantation in its later stages. With the exploration of the use of Rho kinase inhibitors beyond their traditional role in glaucoma therapy, this trial marks a significant advancement in developing pharmacological solutions for unmet needs in FECD management.

How Is The [FECD Market Segmented](#)?

The FECD market as covered in the report angles the market through various segments:

- 1 By Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps
- 2 By Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count, Other Diagnosis
- 3 By Route Of Administration: Oral, Topical, Other Routes Of Administration
- 4 By End-Users: Hospital, Specialty Clinics, Homecare, Other End-Users

Subsegments of the market include:

- 1 By Phototherapeutic Keratectomy: Excimer Laser-Based Phototherapeutic Keratectomy, Femtosecond Laser-Assisted Phototherapeutic Keratectomy, Topography-Guided Phototherapeutic Keratectomy, Manual Epithelial Debridement With Phototherapeutic Keratectomy
- 2 By Amniotic Membrane Transplants: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane, Single-Layer Membrane Transplant, Multi-Layer Membrane Transplant
- 3 By Anterior Stromal Puncture: Manual Needle-Based Puncture, Laser-Assisted Anterior Stromal Puncture, Pattern-Based Puncture, Combination With Bandage Contact Lens
- 4 By Conjunctival Flaps: Total Conjunctival Flap, Partial Or Sectoral Conjunctival Flap, Fornix-Based Flap, Limbal-Based Flap.

What Are The Regional Insights In The FECD Market?

In 2024, North America was observed to be the largest market for FECD market. However, the Asia-Pacific region is expected to be the fastest-growing region in the forecast period. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Corneal Implants Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/corneal-implants-global-market-report>

Corneal Topographers Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/corneal-topographers-global-market-report>

Dry Eye Products Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/dry-eye-products-global-market-report>

[About The Business Research Company](#)

With a portfolio of over 15000+ reports across 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. The company armours you with precise and optimistic information sourced from in-depth secondary research and unique insights from industry leaders, imperative for staying ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas - +1 310-496-7795

Asia: +44 2071930708

Europe - +44 7882 955267

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fl0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/827589091>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.